Welcome to our dedicated page for Telo Genomics news (Ticker: TDSGF), a resource for investors and traders seeking the latest updates and insights on Telo Genomics stock.
Telo Genomics Corp. develops diagnostic and prognostic tests for human disease using 3D analysis of chromosomal telomeres. News about TDSGF centers on the company’s telomere analytics platform, including TeloView® and blood-based minimal residual disease testing for multiple myeloma.
Recurring updates include retrospective clinical studies and academic collaborations, presentations at hematology and myeloma meetings, laboratory-capacity developments, and corporate governance changes. Company announcements also describe work with circulating tumor cells, individual-cell risk profiling, and the use of liquid-biopsy workflows to assess relapse risk in oncology.
Telo Genomics (OTCQB:TDSGF) reported positive interim results from an ongoing retrospective clinical study in multiple myeloma conducted with the National and Kapodistrian University of Athens. The trial evaluates baseline blood samples from patients treated with standard-of-care regimens and known two-year outcomes, comparing those who relapsed with those who remained in remission.
Interim analysis of 50 patients identified “Average Distance to Nuclear Center,” a telomere-associated nuclear architecture parameter linked to genomic instability, as the strongest predictor of relapse status. Receiver Operating Characteristic analysis showed an Area Under the Curve of 0.849, which the company describes as highly predictive. According to Telo Genomics, its blood-based 3D telomere assay may combine minimal residual disease detection, relapse-risk stratification, and longitudinal monitoring in a single test, and could reduce reliance on bone marrow biopsies. The company is also running additional MRD studies with Cleveland Clinic and Montreal Jewish General Hospital and plans broader validation through the end of 2026.
Telo Genomics (OTCQB:TDSGF) filed a U.S. provisional patent to extend its TeloView biomarker algorithm to liquid biopsy MRD applications for multiple myeloma. The patent covers relapse-risk prediction and a workflow for isolating circulating cancer cells, supporting future partnerships and IP protection reportedly through 2043.
Telo Genomics (OTCQB:TDSGF) announced the termination of its investor relations consulting agreement with Sheridan Adams, effective June 12, 2026. The engagement, originally disclosed March 31, 2026, was understood by both parties to be a short-term, transitory role. Telo Genomics extended best wishes to Sheridan.
Telo Genomics (OTCQB: TDSGF) launched a retrospective clinical study with the National and Kapodistrian University of Athens to validate a blood-based 3D telomere assay for MRD in multiple myeloma. The study will compare baseline blood samples to two-year outcomes and aims to match or exceed Euroflow sensitivity.
The company expects results in summer 2026 and renewed CAP laboratory accreditation supports its commercialization pathway and expanded testing capabilities.
Telo Genomics (OTCQB: TDSGF) appointed John Farlinger as chief executive officer and chairman effective March 31, 2026, succeeding founder Dr. Sabine Mai, who remains a director. The company granted Mr. Farlinger 3,700,000 options at $0.055 (50% vested) and engaged Sheridan Adams for investor relations, receiving 250,000 options at $0.05. Telo Genomics expects clinical study results by summer 2026, is beginning work toward a U.S. FDA application, and targets Medicare reimbursement in 2027.
Telo Genomics (OTCQB: TDSGF) appointed John Price as Chief Financial Officer, effective January 30, 2026. Mr. Price brings over three decades of accounting, financial planning, M&A and capital markets experience and succeeds Christopher Ross, who served as CFO since April 2021.
Mr. Price worked at public companies including Assure Holdings, National Beverage, Alliance MMA and MusclePharm, held finance roles at Silicon Valley technology firms, and began his career at Ernst & Young. He holds a B.S. in Accounting from Pennsylvania State University and has no family ties to company directors or officers.
Telo Genomics (OTCQB:TDSGF) launched a retrospective multiple myeloma Minimal Residual Disease (MRD) study with the University of Athens as part of its 2026 multi-center validation program.
The study uses well-characterized blood samples with an average of ~3 years follow-up and existing serial Next-Generation Flow (NGF) MRD results in blood and bone marrow to compare performance to Telo's blood-based TeloView®MRD. TeloView®MRD targets a claimed limit of detection of 1 in 10^7 cells versus NGF sensitivity near 10^6 in some centers. Telo also cites ongoing prospective MRD trials with Cleveland Clinic and Jewish General Hospital and expects additional retrospective collaborations in Q1 2026.
Telo Genomics (OTCQB: TDSGF) presented initial clinical results for a peripheral blood MRD test in multiple myeloma at the 67th ASH meeting on December 11, 2025.
The poster describes a combined approach that enumerates individual circulating tumor cells and applies TeloView 3D telomere profiling, reporting a limit of detection of 1 in 107 cells and identification of distinct 3D genome clusters that correlate with high/low mutation patterns. The abstract was published in Blood and the poster is available on the company website. Larger validation studies are underway to assess predictive power for relapse risk.
Telo Genomics (OTCQB: TDSGF) will present at the Myeloma Canada MRD Testing Implementation Summit on November 14–15, 2025. Dr. Yulia Shifrin will introduce initial clinical results for a blood-based MRD workflow combined with the TeloView® platform that enables individual-cell risk‑profiling.
Early findings report distinct single-cell genomic and structural profiles in myeloma patients that correlate with relapse risk, yielding a quantifiable relapse‑risk score that supplements traditional MRD positivity/negativity.
Telo Genomics (OTCQB: TDSGF) announced that the American Society of Hematology (ASH) accepted its abstract for a poster at the 67th ASH Annual Meeting (Dec 6-9, 2025, Orlando).
Dr. Yulia Shifrin will present Telo's telomere-based Minimal Residual Disease (MRD) methodology that pairs MRD assessment with single-cell risk profiling using the TeloView platform. The abstract will be published in a November supplemental issue of Blood, with full details available after November 3, 2025. The company described the approach as a non-invasive liquid biopsy intended to provide actionable relapse-risk information for clinicians.
Management said ASH acceptance underscores progress toward clinical adoption and broader recognition of Telo's diagnostic technology in the precision oncology diagnostics market.